NewSquare Capital’s Intellia Therapeutics NTLA Stock Holding History

NewSquare Capital’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-10	Closed	-$408	–	796
2023 Q2	$408	Hold	10	–	–	﹤0.01%	702
2023 Q1	$373	Hold	10	–	–	﹤0.01%	737
2022 Q4	$349	Buy	+10	New	+$475	﹤0.01%	686

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

NewSquare Capital's NTLA Position: Q3 2023 in Review

NewSquare Capital sold out of Intellia Therapeutics (NTLA) in Q3 2023, closing a stake of 10 shares — an estimated $408 sold.

NewSquare Capital first reported a position in NTLA in Q4 2022 and held it in 3 quarters. The position peaked at $408 in Q2 2023. 284 funds tracked by Wall St. Rank hold NTLA as of Q3 2023.

NewSquare Capital reported no remaining Intellia Therapeutics position as of Q3 2023 after selling out during the quarter.
NewSquare Capital sold 10 Intellia Therapeutics shares in Q3 2023, an estimated $408.
NewSquare Capital first reported a position in Intellia Therapeutics in Q4 2022 and held it in 3 quarters.
NewSquare Capital's Intellia Therapeutics position peaked at $408 in Q2 2023.
284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.